Watanabe T. Treatment strategies for nodal and gastrointestinal follicular lymphoma: Current status and future development. World J Gastroenterol 2010; 16(44): 5543-5554 [PMID: 21105187 DOI: 10.3748/wjg.v16.i44.5543]
Corresponding Author of This Article
Takuya Watanabe, MD, PhD, Associate Professor, Department of Internal Medicine and Gastroenterology, Medical Hospital, The Nippon Dental University School of Life Dentistry at Niigata, 1-8 Hamauracho, Chu-o-ku, Niigata 951-8580, Japan. nabetaku@dia-net.ne.jp
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Nov 28, 2010; 16(44): 5543-5554 Published online Nov 28, 2010. doi: 10.3748/wjg.v16.i44.5543
Table 1 Lugano staging classification of gastrointestinal tract lymphoma[29]
Stage
I
Tumor confined to GI tract
Stage primary site or multiple, noncontiguous lesions
II
Tumor extending into abdomen from primary GI site
Nodal involvement
II1
Local (paragastric in cases of gastric lymphoma and paraintestinal for intestinal lymphoma)
II2
Distant (mesenteric in the case of an intestinal primary; otherwise paraaortic, paracaval, pelvic, inguinal)
IIE
Penetration of serosa to involve adjacent organs or tissues [enumerate actual site of involvement, e.g. IIE (pancreas), IIE (large intestine), IIE (post intestinal wall)]
Where there is both nodal involvement and penetration involving adjacent organs, the stage is denoted using both a subscript (1 or 2) and E, e.g. II1E (pancreas)
IV
Disseminated extra-nodal involvement, or a GI tract lesion with supradiaphragmatic nodal involvement
Table 2 Results of different randomized trials comparing chemotherapy with chemotherapy plus rituximab in previously untreated patients with follicular lymphoma
Table 4 Results of different randomized trials comparing no maintenance with maintenance therapy with rituximab or interferon after first line therapy in patients with follicular lymphoma
Author(s) or studies, maintenance therapy
No. of patients, target disease and randomization to therapies
Table 5 Results of phase III clinical trials of idiotype vaccines in follicular lymphoma
Study
No. of patients, target disease
Regimen of induction therapy
Eligibility
Vaccine type
Vaccine production methodology
Primary end point
Survival types, P-value, significance
Biovest
n = 177, untreated FL
PACE or R-CHOP
CR
Id-KLH/GM-CSF
Rescue hybridoma
Disease-free survival, P > 0.05, not significant
Genitope
n = 287, untreated FL
CVP
CR, PR
Id-KLH/GM-CSF
Recombinant DNA
Progression-free survival, P > 0.05, not significant
Favrille
n = 349, untreated or recurrent FL
Rituximab
CR, PR, SD
Id-KLH/GM-CSF
Recombinant DNA
Time to progression, P > 0.05, not significant
Citation: Watanabe T. Treatment strategies for nodal and gastrointestinal follicular lymphoma: Current status and future development. World J Gastroenterol 2010; 16(44): 5543-5554